Welcome to our dedicated page for Caribou Biosciences news (Ticker: $CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caribou Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caribou Biosciences's position in the market.
Rhea-AI Summary
CRBU Caribou Biosciences, Inc. reports progress in ANTLER Phase 1 trial and plans to share FDA feedback by year-end 2023. $396.7 million in cash expected to fund operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
-
News
Rhea-AI Summary
Caribou Biosciences, Inc. has appointed Dr. Sundar Jagannath to its scientific advisory board. Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma. He will provide guidance to Caribou as they advance the CaMMouflage Phase 1 trial for CB-011, their allogeneic anti-BCMA CAR-T cell therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.11%
Tags
-
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) will be participating in several investor conferences, including Truist Securities BioPharma Symposium on November 9, Jefferies London Healthcare Conference on November 15, and 6th Annual Evercore ISI HealthCONx Conference on November 30. Webcasts of the events will be available on Caribou's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
Rhea-AI Summary
Caribou Biosciences receives FDA clearance for its allogeneic anti-CLL-1 CAR-T cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
-
Rhea-AI Summary
Caribou Biosciences appoints Reigin Zawadzki as chief people officer to lead people strategy and maintain strong culture. Aim to position for future commercialization. Zawadzki brings 20 years of experience in biotechnology HR. Positive for employee experiences and diversity. No specific numbers mentioned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
-
Rhea-AI Summary
Caribou Biosciences, Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported positive financial results for Q2 2023 and recent business updates, including significant clinical advancements and an equity investment from Pfizer. With more than $400 million in cash, cash equivalents, and marketable securities, Caribou is well-positioned to fund its operations until Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
-
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) has announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a price of $6.50 per share. The gross proceeds to Caribou are expected to be approximately $125 million. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.6%
Tags
-
Rhea-AI Summary
Caribou Biosciences, Inc. has announced a public offering of $100 million of its common stock, with an option for underwriters to purchase an additional $15 million. The offering is subject to market conditions. BofA Securities, Leerink Partners, Evercore ISI, and RBC Capital Markets are the book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.6%
Tags
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported long-term follow-up data from the ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma. The data showed a 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010. The LBCL patient subgroup had a 50% CR rate at ≥6 months. The therapy was generally well-tolerated with adverse events consistent with other CAR-T cell therapies. Caribou is enrolling second-line LBCL patients in the ongoing dose expansion portion of the trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.6%
Tags
Caribou Biosciences, Inc.
Nasdaq:CRBU
CRBU Rankings
CRBU Stock Data
345.92M
68.48M
10.14%
80.55%
11.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
BERKELEY
About CRBU
caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever" and the new york times has noted that "the pace of new discoveries and applications is dizzying." caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub